Investigate Effects of a2 Milk on Breastmilk Composition and Subsequent Infant Gut Health, Crying and Sleep Patterns in Healthy, Full-term Infants

Sponsor
a2 Milk Company Ltd. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05829720
Collaborator
(none)
100
2
2
1.8
50
28.2

Study Details

Study Description

Brief Summary

The goal of this interventional study is to investigate effects of a2 Full Cream Milk on Breastmilk composition and subsequent Infant gut health, crying frequency and sleep patterns in Healthy Full-term Infants.

50 mothers and thier infants will be enrolled into 2 study sites, mother and her child as one subject will be randomized to 2 groups for assigned interventions, a2 Full Cream Milk and conventional Milk (Weidendorf). The study will continue for 14 days, and 3 site visits will be made duing the study period. All data specified in the protocol will be captured and recorded into CTMS for analysis.

Researchers will compare the two groups of participants to see if a2 Full Cream Milk has significantly better breastmilk composition and improve infant's gut health, crying frequency and sleep patterns.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: a2 Full Cream Milk
  • Dietary Supplement: Conventional Milk (Weidendorf)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Supportive Care
Official Title:
A Double-blind, Parallel Designed, Randomized Controlled Trial to Investigate Effects of Conventional vs a2 Milk on Breastmilk Composition and Subsequent Infant Gut Health, Crying and Sleep Patterns in Healthy, Full-term Infants
Anticipated Study Start Date :
Apr 17, 2023
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
Jun 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: a2 Full Cream Milk

a2 Full Cream Milk, 200ml/bag, per 100ml serving Nutrient Composition Energy: 250 kcal Protein:3.2g Fat:3.3g Carbohydrate:4.3g Sodium:40mg Calcium:104mg

Dietary Supplement: a2 Full Cream Milk
Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.

Active Comparator: Conventional Milk (Weidendorf)

Conventional Milk (Weidendorf), 200ml/bag,per 100ml serving Nutrient Composition Energy: 267 kcal Protein:3.3g Fat:3.5g Carbohydrate:4.8g Sodium:50mg Calcium:120mg

Dietary Supplement: Conventional Milk (Weidendorf)
Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.

Outcome Measures

Primary Outcome Measures

  1. Breast milk excretion of Human Milk oligosaccharide content (HMO) content [Baseline (T0)]

    Qualitative analysis of Breast milk excretion of Human Milk oligosaccharide content (HMO) content on baseline day

  2. Breast milk excretion of Human Milk oligosaccharide content (HMO) content [After 14 days of supplementation (T14)]

    Qualitative analysis of Breast milk excretion of Human Milk oligosaccharide content (HMO) content on day 14

  3. Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score [Baseline (T0)]

    Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score, range 10 to 60

  4. Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score [After 14 days of supplementation (T14)]

    Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score, range 10 to 60

Secondary Outcome Measures

  1. Infant Crying Frequency [baseline day, to day 14]

    The Frequency of Infant Crying Daily

  2. Number of Hours of Infants Sleeping [baseline day, to day 14]

    Number of Hours of Infants Sleeping Daily

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Mothers who are 25 to 45 years old;

  • Mothers who are exclusively breastfeeding with healthy and full-term infants;

  • Infants of these mothers who have been exclusively breastfed since birth, and their parent(s) decides to continue exclusively breastfeeding until at least 120 days of age, birth weight between 2500g and 4500g;

  • Willing to sign ICF before the study launched.

Exclusion Criteria:
  • Mothers with infection or have recently taken the flu / covid vaccine in the last 4 weeks;

  • Infant with inborn malformation and with hereditary and/or chronic and/or inborn diseases that could interfere with the survey;

  • Evidence of feeding difficulties or intolerance/allergy to cow's milk (mixed-fed group only);

  • Conditions requiring infant feedings other than those specified in the protocol;

  • Significant systemic disorders (cardiac, respiratory, endocrinological, hematologic, gastrointestinal, or other); or parental refusal to participate;

  • Infants with an acute infection or gastroenteritis at time of enrollment;

  • Participation in another clinical trial;

  • Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jinhua Hospital of TCM, Jinhua Zhejiang China
2 Qiu Bin Community Hospital Jinhua Zhejiang China

Sponsors and Collaborators

  • a2 Milk Company Ltd.

Investigators

  • Principal Investigator: Zhixu Wang, MD, School of Public Health, Nanjing Medical University
  • Principal Investigator: Fan Yang, PhD, West China Second Hospital, Sichuan University
  • Principal Investigator: Yi Sun, MD, Shanghai Tongren Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
a2 Milk Company Ltd.
ClinicalTrials.gov Identifier:
NCT05829720
Other Study ID Numbers:
  • 22-SM-12-A2-001
First Posted:
Apr 26, 2023
Last Update Posted:
Apr 26, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by a2 Milk Company Ltd.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 26, 2023